These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 24119449)

  • 1. CXCR4-derived synthetic peptides inducing anti-HIV-1 antibodies.
    Hashimoto C; Nomura W; Narumi T; Fujino M; Nakahara T; Yamamoto N; Murakami T; Tamamura H
    Bioorg Med Chem; 2013 Nov; 21(22):6878-85. PubMed ID: 24119449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-HIV-1 peptide derivatives based on the HIV-1 Co-receptor CXCR4.
    Hashimoto C; Nomura W; Narumi T; Fujino M; Tsutsumi H; Haseyama M; Yamamoto N; Murakami T; Tamamura H
    ChemMedChem; 2013 Oct; 8(10):1668-72. PubMed ID: 24039179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation of an HIV-1 neutralizing peptide mimicking the CXCR4 and CCR5 surface from the heavy-chain complementary determining region 3 repertoire of a viremic controller.
    Chevigne A; Delhalle S; Counson M; Beaupain N; Rybicki A; Verschueren C; Staub T; Schmit JC; Seguin-Devaux C; Deroo S
    AIDS; 2016 Jan; 30(3):377-82. PubMed ID: 26760231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence as a HIV-1 self-defense vaccine of cyclic chimeric dodecapeptide warped from undecapeptidyl arch of extracellular loop 2 in both CCR5 and CXCR4.
    Misumi S; Takamune N; Ido Y; Hayashi S; Endo M; Mukai R; Tachibana K; Umeda M; Shoji S
    Biochem Biophys Res Commun; 2001 Aug; 285(5):1309-16. PubMed ID: 11478800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring converse molecular mechanisms of anti-HIV-1 antibodies using a synthetic CXCR4 mimic.
    Haussner C; Möbius K; Eichler J
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6099-102. PubMed ID: 22939235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of multiclade R5 and X4 human immunodeficiency virus type-1 infections by a coreceptor-based anti-HIV strategy.
    Nakayama D; Misumi S; Mukai R; Tachibana K; Umeda M; Shibata H; Takamune N; Shoji S
    J Biochem; 2005 Nov; 138(5):571-82. PubMed ID: 16272569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralising properties of peptides derived from CXCR4 extracellular loops towards CXCL12 binding and HIV-1 infection.
    Chevigné A; Fievez V; Szpakowska M; Fischer A; Counson M; Plesséria JM; Schmit JC; Deroo S
    Biochim Biophys Acta; 2014 May; 1843(5):1031-41. PubMed ID: 24480462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection.
    Okuda K; Kaneko T; Yamakawa T; Tanaka S; Shigematsu T; Yamamoto A; Hamajima K; Nakajima K; Kawamoto S; Phanuphak P
    J Mol Recognit; 1993 Sep; 6(3):101-9. PubMed ID: 8060667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong synergistic effects of multicomponent vaccine for human immunodeficiency virus infection.
    Okuda K; Kaneko T; Yamakawa T; Tanaka S; Hamajima K; Shigematsu T; Yamamato A; Kawamoto S
    J Clin Lab Immunol; 1993; 40(3):97-113. PubMed ID: 7877154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-receptor usage was more predictive than NSI/SI phenotype for HIV replication in macrophages: is NSI/SI phenotyping sufficient?
    Lathey JL; Brambilla D; Goodenow MM; Nokta M; Rasheed S; Siwak EB; Bremer JW; Huang DD; Yi Y; Reichelderfer PS; Collman RG
    J Leukoc Biol; 2000 Sep; 68(3):324-30. PubMed ID: 10985247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains.
    Lusso P; Earl PL; Sironi F; Santoro F; Ripamonti C; Scarlatti G; Longhi R; Berger EA; Burastero SE
    J Virol; 2005 Jun; 79(11):6957-68. PubMed ID: 15890935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4.
    Kazmierski WM; Kenakin TP; Gudmundsson KS
    Chem Biol Drug Des; 2006 Jan; 67(1):13-26. PubMed ID: 16492145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel cyclic peptide immunization strategy for preventing HIV-1/AIDS infection and progression.
    Misumi S; Endo M; Mukai R; Tachibana K; Umeda M; Honda T; Takamune N; Shoji S
    J Biol Chem; 2003 Aug; 278(34):32335-43. PubMed ID: 12771150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.
    Labrosse B; Treboute C; Brelot A; Alizon M
    J Virol; 2001 Jun; 75(12):5457-64. PubMed ID: 11356952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raft localization of CXCR4 is primarily required for X4-tropic human immunodeficiency virus type 1 infection.
    Kamiyama H; Yoshii H; Tanaka Y; Sato H; Yamamoto N; Kubo Y
    Virology; 2009 Mar; 386(1):23-31. PubMed ID: 19178925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HIV activity and conformational studies of peptides derived from the C-terminal sequence of SDF-1.
    Dettin M; Pasquato A; Scarinci C; Zanchetta M; De Rossi A; Di Bello C
    J Med Chem; 2004 Jun; 47(12):3058-64. PubMed ID: 15163187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting HIV-1 through molecular modeling and docking studies of CXCR4: leads for therapeutic development.
    Singh S; Malik BK; Sharma DK
    Chem Biol Drug Des; 2007 Mar; 69(3):191-203. PubMed ID: 17441905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication.
    Casoli C; Pilotti E; Perno CF; Balestra E; Polverini E; Cassone A; Conti S; Magliani W; Polonelli L
    AIDS; 2006 Apr; 20(7):975-80. PubMed ID: 16603848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unique monoclonal antibody recognizing the third extracellular loop of CXCR4 induces lymphocyte agglutination and enhances human immunodeficiency virus type 1-mediated syncytium formation and productive infection.
    Tanaka R; Yoshida A; Murakami T; Baba E; Lichtenfeld J; Omori T; Kimura T; Tsurutani N; Fujii N; Wang ZX; Peiper SC; Yamamoto N; Tanaka Y
    J Virol; 2001 Dec; 75(23):11534-43. PubMed ID: 11689635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.